Alto Neuroscience (NYSE:ANRO) Trading Down 6.3% – Time to Sell?

Alto Neuroscience, Inc. (NYSE:ANRO) traded down 6.3% on Tuesday . The company traded as low as $20.89 and last traded at $21.11. 108,239 shares traded hands during mid-day trading, a decline of 58% from the average session volume of 255,021 shares. The stock had previously closed at $22.53.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. JonesTrading reduced their price objective on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Wedbush reduced their price objective on Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating for the company in a research note on Thursday, April 2nd. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Alto Neuroscience in a research note on Thursday, April 2nd. Finally, BTIG Research boosted their price objective on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Alto Neuroscience currently has an average rating of “Moderate Buy” and an average price target of $35.14.

Alto Neuroscience Stock Performance

The firm has a market cap of $672.77 million, a price-to-earnings ratio of -9.71 and a beta of 2.01. The company has a quick ratio of 15.69, a current ratio of 15.69 and a debt-to-equity ratio of 0.12. The stock has a fifty day moving average price of $19.40 and a 200-day moving average price of $15.09.

Alto Neuroscience (NYSE:ANRO) last released its earnings results on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. On average, analysts expect that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. XTX Topco Ltd increased its holdings in shares of Alto Neuroscience by 32.2% in the fourth quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock valued at $371,000 after purchasing an additional 5,078 shares during the period. Ikarian Capital LLC increased its holdings in shares of Alto Neuroscience by 368.2% in the fourth quarter. Ikarian Capital LLC now owns 515,000 shares of the company’s stock valued at $9,167,000 after purchasing an additional 405,000 shares during the period. Vestal Point Capital LP grew its holdings in Alto Neuroscience by 161.6% during the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after acquiring an additional 1,535,000 shares during the period. Wellington Management Group LLP acquired a new position in Alto Neuroscience during the fourth quarter worth $1,228,000. Finally, Perceptive Advisors LLC grew its holdings in Alto Neuroscience by 1,048.5% during the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock worth $31,762,000 after acquiring an additional 1,629,027 shares during the period.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.